EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluating the impact of immunization with the “pan-fungal” vaccine, NXT-2, on the gut mycobiome and microbiome in non-human primates (NHPs)

Kwadwo O Oworae iD, Whitney Rabacal, Anna Hu, Daniel A Wychrij, Emily Rayens, Taylor I Chapman, Justin Bahl iD, Karen A Norris iD

Microbiology Spectrum · 04.08.2026 · 14 (8)

DOI: 10.1128/spectrum.01047-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 04.08.2026. Verfasst von Kwadwo O Oworae und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA. Hauptthemen laut MEDLINE: Fungal Vaccines, Mycobiome, Gastrointestinal Microbiome, Mycoses. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Georgia Research Alliance, University of Georgia Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fungal infections remain a significant public health concern with high mortality, morbidity, and increasing associated health costs. This burden is projected to rise due to expansion of at-risk populations, limited therapeutics, increasing drug resistance, and the emergence of new fungal pathogens. Even with these challenges, there are currently no approved vaccines. We previously developed a “pan-fungal” vaccine candidate, NXT-2, that confers protection against multiple invasive fungal infections such as pulmonary aspergillosis, pneumocystosis, and invasive candidiasis, as well as non-invasive vulvovaginal candidiasis. NXT-2 is a 90 amino acid consensus peptide designed from a conserved region of the fungal antigen (KEX1). We assessed the effect of NXT-2 immunization on gut microbial diversity, composition, and functional capacity in non-human primates. To do this, we monitored changes in the gut mycobiome and microbiome pre- and post-vaccination using ITS2 and metagenomic sequencing, respectively, in Japanese and rhesus macaque cohorts. NXT-2 elicited a robust antibody response without disrupting the gut microbial communities in both macaque species. The mycobiome exhibited stability with no significant changes in alpha and beta diversity, taxonomic composition, or functional guild distributions. The relative abundance of gut resident Candida and Aspergillus species remained stable and was not significantly altered following vaccination. The microbiome showed stability with preserved alpha and beta diversities, taxonomic composition, and functional capacity. Results from this study show the first cross-kingdom analysis demonstrating that antifungal vaccination can achieve protective immunity without perturbing gut microbial communities. This establishes a framework for microbiome-informed vaccine assessment beyond conventional immunogenicity and adverse effect monitoring. IMPORTANCE Fungal infections cause millions of deaths annually, yet no vaccines are approved despite growing drug resistance and limited treatment options. NXT-2 is a pan-fungal vaccine that protects against multiple fungal infections such as pneumocystosis, candidiasis, and aspergillosis. Here, we demonstrate in NHPs that NXT-2 elicits robust protective antibody responses without altering gut bacterial or fungal communities. This is the first study to assess antifungal vaccination across both microbial kingdoms and establish that protective antifungal immunity can be achieved while preserving resident microbiota. This work provides a framework for incorporating microbiome assessment into vaccine development beyond conventional immunogenicity and adverse event monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fungal VaccinesMycobiomeGastrointestinal MicrobiomeMycosesFungiAnimalsMacaca mulattaFemaleAntigens, FungalAntibodies, FungalImmunizationVaccination

Stichwörter der Autor:innen

AspergillusCandidaNXT-2microbiomemycobiomenon-human primatespan-fungal vaccine

Substanzen

Fungal VaccinesAntigens, FungalAntibodies, Fungal

Autor:innen und Institutionen

  • Center for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.
  • Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA.
  • Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.

ORCID-Profile: Kwadwo O Oworae, Justin Bahl, Karen A Norris

Förderung

  • NIAID NIH HHS
  • Georgia Research Alliance
  • University of Georgia Research Foundation
  • National Institute of Allergy and Infectious Diseases
  • College of Veterinary Medicine, University of Georgia

Zitieren

APA

Oworae, K. O., Rabacal, W., Hu, A., Wychrij, D. A., Rayens, E., Chapman, T. I., Bahl, J., & Norris, K. A. (2026). Evaluating the impact of immunization with the “pan-fungal” vaccine, NXT-2, on the gut mycobiome and microbiome in non-human primates (NHPs). Microbiology Spectrum, 14(8). https://doi.org/10.1128/spectrum.01047-26

Vancouver

Oworae KO, Rabacal W, Hu A, Wychrij DA, Rayens E, Chapman TI, et al. Evaluating the impact of immunization with the “pan-fungal” vaccine, NXT-2, on the gut mycobiome and microbiome in non-human primates (NHPs). Microbiology Spectrum. 2026;14(8). doi:10.1128/spectrum.01047-26

BibTeX
@article{Oworae2026,
  author = {Oworae, Kwadwo O and Rabacal, Whitney and Hu, Anna and Wychrij, Daniel A and Rayens, Emily and Chapman, Taylor I and Bahl, Justin and Norris, Karen A},
  title = {Evaluating the impact of immunization with the “pan-fungal” vaccine, NXT-2, on the gut mycobiome and microbiome in non-human primates (NHPs)},
  journal = {Microbiology Spectrum},
  year = {2026},
  volume = {14},
  number = {8},
  doi = {10.1128/spectrum.01047-26}
}
Kostenlos starten →